A star can­cer sci­en­tist failed to dis­close in­dus­try pay­ments over the years — does that mat­ter so much?

Dur­ing the big AS­CO con­fer­ence at the be­gin­ning of last June, promi­nent Memo­r­i­al Sloan Ket­ter­ing sci­en­tist José Basel­ga had this to say about the da­ta he had col­lect­ed for an ex­per­i­men­tal PI3K drug at Roche called taselis­ib:

This is proof that tar­get­ing the PI3K path­way has an ef­fect in breast can­cer and that there are pa­tients who will ben­e­fit. To me that is in­cred­i­bly ex­cit­ing.

Roche, how­ev­er, was not near­ly so en­thu­si­as­tic.

Soon af­ter, the phar­ma gi­ant would dump the whole thing, writ­ing off an­oth­er drug in a se­vere­ly dis­ap­point­ing class that couldn’t muster a strong enough ef­fect to make it worth­while to push it to the mar­ket.

What may not have been well known at the time was that Basel­ga’s en­thu­si­as­tic en­dorse­ment ar­rived af­ter he had col­lect­ed $50,000 in con­sult­ing fees from Roche over the pre­vi­ous four years, and had al­so bagged a $3 mil­lion pay­ment for his share of the sale of Ser­agon, a high-pro­file can­cer biotech that went to Roche for $725 mil­lion.

There isn’t any­thing un­usu­al about those pay­ments. Basel­ga is a high­ly sought af­ter in­ves­ti­ga­tor, board mem­ber and sci­en­tif­ic ad­vis­er and has long been known as one of the top ex­perts in the field — the kind any bio­phar­ma would like to have in its cor­ner. What stands out, though, is that ac­cord­ing to a piece pub­lished by The New York Times and ProP­ub­li­ca over the week­end, Basel­ga has rou­tine­ly failed to dis­close his in­come from a ros­ter of biotech and phar­ma com­pa­nies that he had done work for over the years, both among the jour­nals which ea­ger­ly pub­lished his work as well as or­ga­ni­za­tions like AS­CO, where he head­lined ma­jor pre­sen­ta­tions. 

Basel­ga didn’t de­ny it. He went on to amend his work on 17 pa­pers, but shrugged off nu­mer­ous oth­er in­stances where he hadn’t cit­ed his po­ten­tial con­flicts of in­ter­est, say­ing it was nev­er nec­es­sary. As for the times he had failed to make a nec­es­sary dis­clo­sure about his fi­nan­cial ties, well, he said, his work­ing ties with bio­phar­ma are well known and any such cas­es were sim­ple in­con­sis­ten­cies.

Oth­ers, though, weren’t quite ready to let him off the hook. If some­one of Basel­ga’s stature won’t take these dis­clo­sures se­ri­ous­ly, why would any­one?

“If lead­ers don’t fol­low the rules, then we don’t re­al­ly have rules,” Walid Gel­lad, di­rec­tor of the Cen­ter for Phar­ma­ceu­ti­cal Pol­i­cy and Pre­scrib­ing at the Uni­ver­si­ty of Pitts­burgh, told the au­thors of the re­port. “It says that the rules don’t mat­ter.”

The ab­sence of Basel­ga’s ros­ter of in­dus­try con­flicts al­so eras­es some im­por­tant con­text for his en­dorse­ments of ex­per­i­men­tal drugs, like taselis­ib.

The re­port trig­gered some in­ter­est­ing chat­ter on Twit­ter over the last two days. And we have a snap poll on the is­sue we’d like you to par­tic­i­pate in, which you can see be­low the Twit­ter ex­change.


Snap poll for End­points read­ers

Im­age: José Basel­ga. AU­RA BIO­SCIENCES

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

David Meline (file photo)

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the com­pen­sa­tion pack­age

David Meline took a little off the top of his salary when he jumped from the CFO post at giant Amgen to become the numbers czar at the upstart vaccines revolutionary Moderna. But the SEC filing that goes with a major hire also illustrates how it puts him in line for a fortune — provided the biotech player makes good as a promising game changer.

To be sure, there’s nothing wrong with the base salary: $600,000. Or the up-to 50% annual cash bonus — an industry standard — that comes with it. True, the 62-year-old earned $999,000 at Amgen in 2019, but it’s the stock options that really count in the current market bliss for all things biopharma. And there Meline did well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.

Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.